HB F estimation in bilharzial hepatosplenomegaly

Hb F was estimated in 60 persons: 20 normal persons representing group I, 20 patients suffering from Schistozoma mansoni infection without hepatosplenomegaly [Group II] and 20 patients suffering from schistozoma mansoni infection with hepatosplenomegally [Group Ill]. Hb estimation and Hb F detection and quantitation by three different methods: alkali denaturation, acid ellution and Hb electrophoretic mobility were performed. Counting the number of Schistozoma mansoni ovae in stool was done by Modified Kato technique.Results showed absence of Hb F in blood of bilharzial patients. This may be due to absence of causes that increase Hb F as intense erythropoiesis of other responsible factors

Studies on the induction of stable and prolonged hyperglycemia by subdiabetogenic dose of streptozotocin [STZ]

The experiments proved that STZ in doses ranging between 35-62 mg/Kg causes mortality within 24 hours. Determination of sublethal dose proved that 27.5 mg/Kg STZ was safe and induced mild diabetogenic effects. Increasing the diabetogenic efficiency of STZ was conducted by four booster doses amounting to 11.25 mg/Kg/dose administered weekly. The data proved the incidence of hyperglycemia maintained over 45 days from the initial dose. STZ-hyperglycemia was characterized by two phases: first grade where mild elevation in blood sugar level was indicated and second grade, accompanied by highly significant hyperglycemia

Effect of STZ induced hyperglycemia on circulating insulin and glucagon

Streptozotocin [STZ] hyperglycemia was induced by subcutaneous injection of initial dose amounting to 27.5 mg/Kg, followed by four booster doses amounting to 11.25 mg/Kg administered weekly to the test rats. The diabetogenic effect of STZ over 45 days comprises three stages of hyperglycemia. During the first stage, STZ caused hypersecretion of glucagon followed by an increase of c-AMP. Secondly, using a higher dose of STZ, the hypersecretion of glucagon was followed by a well marked increase of the insulin level. The elevation of c-AMP persisted. Lastly, severe diabetes, coupled with very highly significant reduction in the level of insulin, was indicated at the end of the experimental period